AstraZeneca lung cancer drug receives FDA approval
European Pharmaceutical Review | April 04, 2017
The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR).